Trade Name: Albuterol Sulfate

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Nucare Pharmaceuticals, Inc.

Presentation: SOLUTION, HUMAN PRESCRIPTION DRUG

Strength: 2.5 mg/3mL

Storage and handling

ALBUTEROL SULFATE Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC]

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • *Potency expressed as albuterol, equivalent to 3 mg albuterol sulfate.
  • PRESCRIBING INFORMATION
  • FOR INHALATION USE ONLY u2013 NOT FOR INJECTION.
  • Albuterol sulfate inhalation solution is a relatively selective betan n n -adrenergic bronchodilator (see n n n section below). Albuterol sulfate, the racemic form of albuterol, has the chemical name u03b1n n n -[(n n n -Butylamino)methyl]-4-hydroxy-n n n -xylene-u03b1,u03b1u2032-diol sulfate (2:1) (salt) and the following structural formula:n nn
  • Albuterol sulfate has a molecular weight of 576.7, and the molecular formula is (Cn n n Hn n n NOn n n )n n n u2022Hn n n SOn n n . Albuterol sulfate is a white or practically white powder, freely soluble in water and slightly soluble in alcohol. The World Health Organizationu2019s recommended name for albuterol base is salbutamol. Albuterol sulfate inhalation solution 0.083% requires no dilution before administration.n nn
  • Each mL of albuterol sulfate inhalation solution (0.083%) contains 0.83 mg of albuterol (as 1 mg of albuterol sulfate) in an isotonic, sterile, aqueous solution containing sodium chloride; sulfuric acid is used to adjust the pH to between 3 and 5. Albuterol sulfate inhalation solution (0.083%) contains no sulfiting agents. Albuterol sulfate inhalation solution is a clear, colorless solution.
  • The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. n n n studies and n n n pharmacologic studies have demonstrated that albuterol has a preferential effect on betan n n -adrenergic receptors compared with isoproterenol. While it is recognized that betan n n -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that 10% to 50% of the beta-receptors in the human heart may be betan n n -receptors. The precise function of these receptors, however, is not yet established. Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract in the form of bronchial smooth muscle relaxation than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.n nn
  • Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-n n n -methyl transferase.n nn
  • Studies in asthmatic patients have shown that less than 20% of a single albuterol dose was absorbed following either IPPB (intermittent positive-pressure breathing) or nebulizer administration; the remaining amount was recovered from the nebulizer and apparatus and expired air. Most of the absorbed dose was recovered in the urine 24 hours after drug administration. Following a 3 mg dose of nebulized albuterol, the maximum albuterol plasma level at 0.5 hours was 2.1 ng/mL (range, 1.4 to 3.2 ng/mL).
  • There was a significant dose-related response in FEVn n n (forced expiratory volume in one second) and peak flow rate. It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was five to six hours.n nn
  • Animal studies show that albuterol does not pass the blood-brain barrier. Recent studies in laboratory animals (minipigs, rodents, and dogs) recorded the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The significance of these findings when applied to humans is currently unknown.
  • In controlled clinical trials, most patients exhibited an onset of improvement in pulmonary function within 5 minutes as determined by FEVn n n . FEVn n n measurements also showed that the maximum average improvement in pulmonary function usually occurred at approximately 1 hour following inhalation of 2.5 mg of albuterol by compressor-nebulizer and remained close to peak for 2 hours. Clinically significant improvement in pulmonary function (defined as maintenance of a 15% or more increase in FEVn n n over baseline values) continued for 3 to 4 hours in most patients and in some patients continued up to 6 hours.n nn
  • In repetitive dose studies, continued effectiveness was demonstrated throughout the three-month period of treatment in some patients.
  • Published reports of trials in asthmatic children aged 3 years or older have demonstrated significant improvement in either FEVn n n or PEFR within 2 to 20 minutes following a single dose of albuterol inhalation solution. An increase of 15% or more in baseline FEVn n n has been observed in children aged 5 to 11 years up to 6 hours after treatment with doses of 0.10 mg/kg or higher of albuterol inhalation solution. Single doses of 3, 4, or 10 mg resulted in improvement in baseline PEFR that was comparable in extent and duration to a 2 mg dose, but doses above 3 mg were associated with heart rate increases of more than 10%.n nn
  • Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
  • Albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.
  • As with other inhaled beta-adrenergic agonists, albuterol sulfate inhalation solution can produce paradoxical bronchospasm, which can be life threatening. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted.
  • Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs and with the home use of nebulizers. It is, therefore, essential that the physician instruct the patient in the need for further evaluation, if his/her asthma becomes worse. In individual patients, any betan n n -adrenergic agonist, including albuterol solution for inhalation, may have a clinically significant cardiac effect.n nn
  • Immediate hypersensitivity reactions may occur after administration of albuterol as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.
  • No data
  • The results of clinical trials with albuterol sulfate inhalation solution in 135 patients showed the following side effects which were considered probably or possibly drug related:
  • Central Nervous System:
  • Gastrointestinal:
  • Ear, Nose and Throat:
  • Cardiovascular:
  • Respiratory:
  • No clinically relevant laboratory abnormalities related to albuterol sulfate inhalation solution administration were determined in these studies.
  • In comparing the adverse reactions reported for patients treated with albuterol sulfate inhalation solution with those of patients treated with isoproterenol during clinical trials of three months, the following moderate to severe reactions, as judged by the investigators, were reported. This table does not include mild reactions.
  • *The finding of no arrhythmias and no palpitations after albuterol administration in the clinical study should not be interpreted as indicating that these adverse effects cannot occur after the administration of inhaled albuterol.
  • +In most cases of bronchospasm, this term was generally used to describe exacerbations in the underlying pulmonary disease. Cases of urticaria, angioedema, rash, bronchospasm, hoarseness, oropharyngeal edema, arrhythmias (including atrial fibrillations, supraventricular tachycardia, extrasystoles) have been reported after the use of albuterol sulfate inhalation solution.
  • Manifestations of overdosage may include seizures, anginal pain, hypertension, hypokalemia, tachycardia with rates up to 200 beats/min, and exaggeration of the pharmacological effects listed in n n n . In isolated cases in children 2 to 12 years of age, tachycardia with rates > 200 beats/min has been observed.n nn
  • The oral LDn n n in rats and mice was greater than 2,000 mg/kg. The inhalation LDn n n could not be determined.n nn
  • There is insufficient evidence to determine if dialysis is beneficial for overdosage of albuterol inhalation solution.
  • Adults and Children 2 to 12 Years of Age:
  • The use of albuterol sulfate inhalation solution can be continued as medically indicated to control recurring bouts of bronchospasm. During this time most patients gain optimum benefit from regular use of the inhalation solution.
  • If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of seriously worsening asthma that would require reassessment of therapy.
  • Unit-dose plastic vial containing sterile Albuterol Sulfate Inhalation Solution 0.083%, 2.5 mg* / 3 ml (*Potency expressed as albuterol, equivalent to 3 mg albuterol sulfate). Equivalent to 0.5 mL of albuterol sulfate inhalation solution, 0.5% diluted to 3 mL with normal saline. Supplied in cartons as listed below.
  • NDC 66267-746-06: 6 vials per bottle
  • PROTECT FROM LIGHT. Store vials in pouch until time of use. Store between 2u00b0 and 25u00b0 C (36u00b0 and 77u00b0 F).
  • Rx Only
  • Manufactured By:
  • Nephron Pharmaceuticals Corporation
  • Orlando, FL 32811
  • For Customer Service,
  • Call 1-800-443-4313
  • Albuterol Sulfate Inhalation Solution, 0.083%*
  • 2.5 mg*/3 mL
  • *Potency expressed as albuterol, equivalent to 3 mg albuterol sulfate.
  • Note: This is a unit-dose vial.u00a0 No dilution is required.u00a0 Read complete instructions carefully before using.
  • Note: Use only as directed by your physician. More frequent administration or higher doses are not recommended.
  • Store Albuterol Sulfate Inhalation Solution, 0.083%* between 2u00b0 and 25u00b0 C (36u00b0 and 77u00b0 F). Store vials in pouch until time of use.
  • No data

Ask for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of Albuterol Sulfate (Albuterol Sulfate) which is also known as Albuterol Sulfate and Manufactured by Nucare Pharmaceuticals, Inc.. It is available in strength of 2.5 mg/3mL.

Albuterol Sulfate (Albuterol Sulfate) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

BENZALKONIUM CHLORIDE - 1 (nickelodeon bright bubble gum scented hand sanitizer)

BENZALKONIUM CHLORIDE - 1 (nickelodeon bright bubble gum scented hand sanitizer)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Are you an existing customer or a vendor of GNH India? Log in here to